Bio-Path Holdings BPTH

Bio-Path Holdings, Inc. is a clinical and preclinical stage biopharmaceutical company focused on developing RNAi nanoparticle therapeutics for oncology and obesity-related metabolic diseases. Its core technology, DNAbilize®, utilizes a P-ethoxy-modified DNA backbone encapsulated in a neutral-charge lipid bilayer to enable systemic delivery of antisense drugs that inhibit disease-causing proteins. This platform aims to overcome historical challenges in antisense therapeutics, such as instability and inefficient cellular uptake, by providing a non-toxic delivery mechanism with demonstrated safety in preclinical and clinical studies.

Bio-Path Holdings, Inc. generates revenue through the advancement of its drug development pipeline, with potential future income from licensing, partnerships, or commercialization of its DNAbilize® platform and therapeutic candidates. The company does not currently have commercial products or sales revenue, as its focus remains on preclinical and clinical-stage research and development. Revenue generation is expected to arise from successful clinical milestones, regulatory approvals, and strategic collaborations with pharmaceutical or academic institutions.

The company operates through the following segments:

• Prexigebersen (BP1001): This segment focuses on the development of prexigebersen, an antisense drug targeting the Grb2 protein, initially for acute myeloid leukemia (AML) in combination with decitabine and venetoclax. Prexigebersen is delivered via the DNAbilize® platform and has demonstrated antitumor activity in preclinical models and clinical trials. The drug substance is also used in BP1001-A, a modified formulation designed to enhance nanoparticle properties for solid tumor and metabolic disease indications.
• BP1002 (Liposomal Bcl-2): This segment develops BP1002, an antisense drug targeting the Bcl-2 protein for hematologic malignancies such as lymphoma, chronic lymphocytic leukemia (CLL), and AML, particularly in venetoclax-resistant patients. BP1002 utilizes the DNAbilize® delivery system to inhibit Bcl-2 mRNA and overcome resistance mechanisms. Clinical trials are ongoing at major cancer centers including Weill Medical College, MD Anderson, Scripps Health, and UCLA.
• BP1003 (Liposomal STAT3): This segment advances BP1003, an antisense drug targeting the STAT3 transcription factor for solid tumors, with lead indications in pancreatic cancer and non-small cell lung cancer (NSCLC). BP1003 uses the DNAbilize® platform to penetrate fibrotic tumor stroma and modulate the tumor microenvironment. Preclinical studies have shown enhanced chemotherapy sensitivity in breast, ovarian, and pancreatic cancer models, with IND-enabling studies completed or underway.
• BP1001-A: This segment develops BP1001-A, a modified version of prexigebersen with formulation enhancements to create smaller nanoparticles for improved tumor penetration. It is being evaluated for solid tumors including ovarian, endometrial, pancreatic, and breast cancers, as well as for obesity and Type 2 diabetes by targeting Grb2-mediated insulin resistance. Clinical trials are ongoing at institutions such as MD Anderson, Karmanos Cancer Institute, and Mary Crowley Cancer Research.

Bio-Path Holdings, Inc. operates in a highly competitive biotechnology landscape focused on targeted nucleic acid therapeutics, facing competition from larger pharmaceutical companies with greater resources, established pipelines, and regulatory expertise. Its competitive advantage lies in the proprietary DNAbilize® delivery technology, which combines P-ethoxy-modified antisense DNA with neutral liposomes to achieve efficient, systemic delivery with a favorable safety profile. The company differentiates itself by targeting specific disease-driving proteins such as Grb2, Bcl-2, and STAT3, aiming to minimize off-target effects compared to broader-acting small molecule inhibitors.

Bio-Path Holdings, Inc. serves patients with hematologic malignancies such as acute myeloid leukemia, lymphoma, and chronic lymphocytic leukemia, as well as those with solid tumors including pancreatic, ovarian, endometrial, and breast cancers. The company also targets individuals with obesity and Type 2 diabetes through its metabolic disease programs. Clinical trial sites include leading cancer centers such as Weill Medical College of Cornell University, MD Anderson Cancer Center, Scripps Health, UCLA, Georgia Cancer Center, UT Southwestern, New York Medical College, Karmanos Cancer Institute, Mary Crowley Cancer Research, and Holy Cross Hospital.